This site is intended for healthcare professionals residing in Canada.

Visit Pfizer AcademySearch

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
ContentGo to Explore ContentEventsMaterialsVideosPatient SupportContact
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

About Prevnar 13About Prevnar 13Mechanism of ActionSerotype coverageIncidence of IPD and Colonization dataExperienceImmunogenicityDosingDosingDosingEfficacy and Safety ProfileEfficacy and Safety ProfileEfficacy profileSafety profileGuidelinesGuidelinesGuidelinesResourcesResourcesMaterialsVideos
Product MonographImportant Safety Information 
Demonstrated efficacy profile

There are no randomized, placebo-controlled trials of Prevnar 13 against AOM and pneumonia. However, the efficacy and effectiveness of Prevnar (7-valent) has been established for invasive disease, pneumonia, and otitis media.1

In an observational study in Quebec after the implementation of a publicly funded program in all children, the effectiveness of Prevnar (7-valent) against AOM and pneumonia was studied using    a 3-dose immunization schedule (2-dose in the first year of life with a booster dose in the second year). This 3-dose immunization schedule is not recommended for Prevnar 13.

Prevnar (Pneumococcal 7-valent Conjugate Vaccine) has been discontinued in Canada.

Available efficacy data of Prevnar (7-valent)

Pneumonia

AOM

Tab Number 3

Tab Number 4

Tab Number 5

In the 3 years following Prevnar 7 introduction for pneumonia

~13% observed reduction in hospital admissions for all-cause pneumonia with no increase in cases of empyema.

While direct cause-and-effect cannot be concluded from observational analysis of this type, these findings suggest that Prevnar (7-valent) plays an important role in reducing the burden of mucosal disease (AOM and pneumonia) in the target population.AOM: acute otitis media.
In the 3 years following Prevnar 7 introduction for acute otitis media (AOM)*

~13.2% observed reduction in otitis media claims attributable to Prevnar (7-valent).

~100,000 otitis media visits averted in children under 5 years of age (estimated over 3 years).

While direct cause-and-effect cannot be concluded from observational analysis of this type, these findings suggest that Prevnar (7-valent) plays an important role in reducing the burden of mucosal disease (AOM and pneumonia) in the target population.
Reference:Prevnar® 13 Product Monograph. Pfizer Canada ULC. 2022.Efficacy and safety profile
NEXT

Safety profile

 Visit page Loading
EXPLORE MORE

Immunogenicity data

 Visit page Loading
PP-PRV-CAN-0016-EN

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN